Richard Buchholz Sells 11,000 Shares of Inspire Medical Systems (NYSE:INSP) Stock

Key Points

• Richard Buchholz, CFO of Inspire Medical Systems, sold 11,000 shares at an average price of $93.39, reducing his total ownership in the company by 19.69%.
• Inspire Medical Systems reported earnings of $0.45 per share for the last quarter, exceeding estimates and reflecting a 10.8% year-over-year revenue increase.
• The company has authorized a $200 million stock repurchase plan, indicating the board's belief that its stock is undervalued.

Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report) CFO Richard Buchholz sold 11,000 shares of Inspire Medical Systems stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $93.39, for a total value of $1,027,290.00. Following the completion of the sale, the chief financial officer directly owned 44,867 shares of the company's stock, valued at approximately $4,190,129.13. This trade represents a 19.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Inspire Medical Systems Stock Up 0.1%

INSP traded up $0.08 during trading hours on Friday, hitting $86.40. The stock had a trading volume of 924,970 shares, compared to its average volume of 997,672. The company's fifty day simple moving average is $109.67 and its 200 day simple moving average is $138.36. Inspire Medical Systems, Inc. has a 1 year low of $73.92 and a 1 year high of $225.00. The stock has a market cap of $2.55 billion, a PE ratio of 49.94, a price-to-earnings-growth ratio of 2.69 and a beta of 1.15.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.23. Inspire Medical Systems had a return on equity of 10.38% and a net margin of 6.17%.The company had revenue of $217.09 million during the quarter, compared to analyst estimates of $214.50 million. During the same quarter last year, the firm posted $0.32 EPS. The firm's revenue for the quarter was up 10.8% on a year-over-year basis. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. As a group, equities analysts expect that Inspire Medical Systems, Inc. will post 2.16 EPS for the current year.

Inspire Medical Systems announced that its Board of Directors has authorized a stock repurchase program on Monday, August 11th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to reacquire up to 8.6% of its shares through open market purchases. Shares repurchase programs are often an indication that the company's board believes its stock is undervalued.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of INSP. Northern Trust Corp grew its holdings in shares of Inspire Medical Systems by 40.2% during the fourth quarter. Northern Trust Corp now owns 244,249 shares of the company's stock worth $45,279,000 after purchasing an additional 69,995 shares in the last quarter. Comerica Bank grew its holdings in shares of Inspire Medical Systems by 26.6% during the fourth quarter. Comerica Bank now owns 25,159 shares of the company's stock worth $4,664,000 after purchasing an additional 5,285 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec purchased a new position in shares of Inspire Medical Systems during the fourth quarter worth about $738,000. BNP Paribas Financial Markets grew its holdings in shares of Inspire Medical Systems by 69.6% during the fourth quarter. BNP Paribas Financial Markets now owns 7,991 shares of the company's stock worth $1,481,000 after purchasing an additional 3,280 shares in the last quarter. Finally, Captrust Financial Advisors grew its holdings in shares of Inspire Medical Systems by 2.0% during the fourth quarter. Captrust Financial Advisors now owns 3,034 shares of the company's stock worth $562,000 after purchasing an additional 59 shares in the last quarter. Hedge funds and other institutional investors own 94.91% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on INSP shares. JPMorgan Chase & Co. lowered Inspire Medical Systems from an "overweight" rating to a "neutral" rating and decreased their price objective for the stock from $195.00 to $110.00 in a report on Tuesday, August 5th. Wall Street Zen lowered Inspire Medical Systems from a "buy" rating to a "hold" rating in a report on Saturday, July 26th. Stifel Nicolaus set a $140.00 target price on Inspire Medical Systems and gave the company a "hold" rating in a report on Tuesday, August 5th. Lake Street Capital set a $150.00 target price on Inspire Medical Systems and gave the company a "buy" rating in a report on Tuesday, August 5th. Finally, Royal Bank Of Canada reduced their target price on Inspire Medical Systems from $215.00 to $180.00 and set an "outperform" rating for the company in a report on Tuesday, August 5th. Eight research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $164.50.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.